article thumbnail

Eric Halioua, President & CEO at PDC*line Pharma Shares Insights on the Results from P-I/II Trial with PDC*lung01

PharmaShots

These new results reinforce our differentiating data package for PDC*lung01. We are very pleased to demonstrate that our innovative immunotherapy platform can induce a strong immune response in humans. We reported at ESMO-IO the analysis of immune response of the first 3 cohorts of patients. 2015; Zhu et al., 2015; Zhu et al.,